Why Investors Don’t Care About This Sarepta News

The Department of Defense officially terminated its contract with biotech company Sarepta (NASDAQ: SRPT  ) for the development of an Ebola virus drug this week. While the company will continue to develop its Marburg virus drug under this contract, did the cancellation of this project have an effect on the company's share price? Didn't Sarepta have a stellar week after it released data related to its Duchenne's muscular dystrophy drug eteplirsen?

In the following video, health-care analysts Max Macaluso and David Williamson discuss this news and what investors should be watching at Sarepta going forward.

Sarepta's share price popped this week, but it wasn't The Motley Fool's Top Stock for 2012. To find out what it is before the rest of the market catches on, click here -- it's absolutely free.

Max Macaluso, David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2046696, ~/Articles/ArticleHandler.aspx, 4/19/2014 2:17:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement